FDA
-
-
-
-
-
-
-
PTC Therapeutics reports Q4 Sephience revenue of $92.5 million
-
-
-
-
-
-
-
Goldman Sachs Reiterates Sell Rating on PTC Therapeutics (PTCT)
-
-
-
-
-
-
-
PTC Therapeutics (PTCT) PT Raised to $80 at UBS
-
-
-
-
-
-
-
RBC Capital Reiterates Outperform Rating on PTC Therapeutics (PTCT)
-
-
-
-
-
-
-
BofA Securities Upgrades PTC Therapeutics (PTCT) to Neutral
-
-
-
-
-
-
-
PTC Therapeutics Provides Update on Commercial Performance and R&D Pipeline at 43rd Annual J.P. Morgan Healthcare Conference
-
-
-
-
-
-
-
PTC Therapeutics Enters into Agreement to Sell Priority Review Voucher for $150 Million
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

